New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIpamorelin vs IGF-1 DES

Ipamorelin vs IGF-1 DES

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Ipamorelin
Anabolic & IGF
IGF-1 DES
Summary
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
IGF-1 DES (also written DES(1-3)IGF-1) is a truncated form of IGF-1 missing the first three amino acids of the N-terminus. This structural change dramatically reduces its affinity for IGF binding proteins (IGFBPs), meaning a far greater fraction remains in its free, active form. IGF-1 DES is estimated to be 10x more potent than standard IGF-1 LR3 at the receptor level locally, making it particularly effective for site-specific muscle growth when injected intramuscularly.
Half-Life
2 hours
~20–30 minutes (very short — designed for local action)
Admin Route
SubQ
IM, SubQ
Research
Typical Dose
100–300 mcg
20–50 mcg per injection site
Frequency
Once to twice daily
Once daily, post-workout
Key Benefits
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
  • Estimated 10x greater potency at the receptor vs IGF-1 LR3 locally
  • Minimal IGFBP binding — nearly all active upon injection
  • Highly localized muscle growth effect when injected intramuscularly
  • Activates satellite cells for muscle fiber hyperplasia potential
  • Synergistic with GH peptides in post-workout anabolic protocols
  • Shorter half-life reduces systemic exposure vs IGF-1 LR3
  • Useful for site-specific muscle development
Side Effects
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
  • Hypoglycemia (most significant risk — especially post-workout)
  • Localized muscle swelling at injection site
  • Potential for jaw/organ growth (acromegalic effects) with prolonged high-dose use
  • Carpal tunnel syndrome with high doses
  • +1 more
Stacks With